Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H GILBERT

Showing results (771-780 of 824) with videos related to

Pageof 83
Sort By:
ACS Infectious Diseases|October 3, 2017
Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovaniLeah S Torrie, Stephen Brand, David A Robinson, et al.
Progress in Biophysics and Molecular Biology|July 23, 2011
Towards a computational reconstruction of the electrodynamics of premature and full term human labourO Aslanidi, J Atia, A P Benson, et al.
Microbiology Spectrum|February 27, 2023
<i>In Vitro</i> Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing <i>Enterobacterales</i> Collected in IndiaYamuna Devi Bakthavatchalam, Divyaa Elangovan, Subha Vajjiravelu Jaganathan, et al.
ACS Infectious Diseases|April 21, 2023
Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022Nicola Caldwell, Rana Afshar, Beatriz Baragaña, et al.
Science Advances|March 7, 2025
Trained immunity causes myeloid cell hypercoagulabilityAisling M Rehill, Seán McCluskey, Anna E Ledwith, et al.
ACS Infectious Diseases|January 23, 2020
The Q<sub>i</sub> Site of Cytochrome <i>b</i> is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i>Richard J Wall, Sandra Carvalho, Rachel Milne, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Small molecule inhibitors of the NorA multidrug efflux pump potentiate antibiotic activity by binding the outward-open conformationJanine L Gray, Elizabeth V K Ledger, Tiffany Suwatthee, et al.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
ACS Infectious Diseases|November 2, 2018
Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovaniVictoriano Corpas-Lopez, Sonia Moniz, Michael Thomas, et al.
Journal of Medicinal Chemistry|July 15, 2020
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> ActivityMichael G Thomas, Manu De Rycker, Richard J Wall, et al.
Pageof 83

Showing results (771-780 of 824) with videos related to

Sort By:
Pageof 83
ACS Infectious Diseases|October 3, 2017
Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovaniLeah S Torrie, Stephen Brand, David A Robinson, et al.
Progress in Biophysics and Molecular Biology|July 23, 2011
Towards a computational reconstruction of the electrodynamics of premature and full term human labourO Aslanidi, J Atia, A P Benson, et al.
Microbiology Spectrum|February 27, 2023
<i>In Vitro</i> Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing <i>Enterobacterales</i> Collected in IndiaYamuna Devi Bakthavatchalam, Divyaa Elangovan, Subha Vajjiravelu Jaganathan, et al.
ACS Infectious Diseases|April 21, 2023
Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022Nicola Caldwell, Rana Afshar, Beatriz Baragaña, et al.
Science Advances|March 7, 2025
Trained immunity causes myeloid cell hypercoagulabilityAisling M Rehill, Seán McCluskey, Anna E Ledwith, et al.
ACS Infectious Diseases|January 23, 2020
The Q<sub>i</sub> Site of Cytochrome <i>b</i> is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i>Richard J Wall, Sandra Carvalho, Rachel Milne, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Small molecule inhibitors of the NorA multidrug efflux pump potentiate antibiotic activity by binding the outward-open conformationJanine L Gray, Elizabeth V K Ledger, Tiffany Suwatthee, et al.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
ACS Infectious Diseases|November 2, 2018
Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovaniVictoriano Corpas-Lopez, Sonia Moniz, Michael Thomas, et al.
Journal of Medicinal Chemistry|July 15, 2020
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> ActivityMichael G Thomas, Manu De Rycker, Richard J Wall, et al.
Pageof 83